Verica Milivojevic1, Gustavo A Angarita2, Gretchen Hermes1, Rajita Sinha1, Helen C Fox3. 1. From the, Department of Psychiatry, (VM, GH, RS), The Yale Stress Center, Yale University School of Medicine, New Haven, Connecticut. 2. Clinical Neuroscience Research Unit, (GAA), Department of Psychiatry, Connecticut Mental Health Center, Yale University School of Medicine, New Haven, Connecticut. 3. Department of Psychiatry, (HCF), Stony Brook University School of Medicine, Stony Brook, New York.
Abstract
BACKGROUND: Chronic alcohol use results in changes to stress biology and autonomic arousal contributing to acute alcohol withdrawal symptoms, neuroendocrine tolerance of the hypothalamic-pituitary-adrenal axis responses, high stress-induced craving, and risk of alcohol relapse. Thus, stress coping and recovery from alcohol during early abstinence may be jeopardized by such stress system dysfunction. Significant preclinical evidence suggests that noradrenergic disruption may contribute to these alcohol-related stress arousal changes and that alpha-1 adrenergic antagonists, such as prazosin, may normalize these stress system adaptations and reduce alcohol intake. Thus, we hypothesized that prazosin would reduce stress-induced craving and improve neuroendocrine and autonomic response to stress and alcohol cue exposure during early abstinence. We secondarily also assessed the role of lifetime anxiety disorders on these prazosin effects. METHODS:Forty inpatient treatment-seeking alcohol-dependent individuals were randomly assigned to receive placebo (n = 18) or 16 mg/d, T.I.D., prazosin (n = 22) in a double-blind manner, titrated over 2 weeks. In weeks 3 to 4 after achieving full dose, patients were exposed to 3 5-minute personalized guided imagery conditions (stress cue, alcohol cue, neutral/relaxing cue), on 3 consecutive days in a random, counterbalanced order. Alcohol craving, anxiety, heart rate, cortisol, and adrenocorticotropic hormone (ACTH) levels were assessed at baseline, following imagery and at repeated recovery timepoints. RESULTS: Prazosin reduced stress cue-induced alcohol craving (p < 0.05) and stress- and alcohol cue-induced anxiety (p < 0.05) and increased heart rate responses in all imagery conditions (p < 0.05). Prazosin lowered basal cortisol and ACTH (p's < 0.05) and attenuated stress cue-induced rises in cortisol (p < 0.05) versus placebo. Finally, in those without lifetime anxiety disorder, the placebo group showed stress- and alcohol cue-induced increases in cortisol (p's < 0.05), while the prazosin group did not. CONCLUSIONS: Prazosin may attenuate stress cue-induced alcohol craving and anxiety during early abstinence while improving adrenergic and stress system function, effects which are independent of a history of lifetime anxiety disorders.
RCT Entities:
BACKGROUND: Chronic alcohol use results in changes to stress biology and autonomic arousal contributing to acute alcohol withdrawal symptoms, neuroendocrine tolerance of the hypothalamic-pituitary-adrenal axis responses, high stress-induced craving, and risk of alcohol relapse. Thus, stress coping and recovery from alcohol during early abstinence may be jeopardized by such stress system dysfunction. Significant preclinical evidence suggests that noradrenergic disruption may contribute to these alcohol-related stress arousal changes and that alpha-1 adrenergic antagonists, such as prazosin, may normalize these stress system adaptations and reduce alcohol intake. Thus, we hypothesized that prazosin would reduce stress-induced craving and improve neuroendocrine and autonomic response to stress and alcohol cue exposure during early abstinence. We secondarily also assessed the role of lifetime anxiety disorders on these prazosin effects. METHODS: Forty inpatient treatment-seeking alcohol-dependent individuals were randomly assigned to receive placebo (n = 18) or 16 mg/d, T.I.D., prazosin (n = 22) in a double-blind manner, titrated over 2 weeks. In weeks 3 to 4 after achieving full dose, patients were exposed to 3 5-minute personalized guided imagery conditions (stress cue, alcohol cue, neutral/relaxing cue), on 3 consecutive days in a random, counterbalanced order. Alcohol craving, anxiety, heart rate, cortisol, and adrenocorticotropic hormone (ACTH) levels were assessed at baseline, following imagery and at repeated recovery timepoints. RESULTS:Prazosin reduced stress cue-induced alcohol craving (p < 0.05) and stress- and alcohol cue-induced anxiety (p < 0.05) and increased heart rate responses in all imagery conditions (p < 0.05). Prazosin lowered basal cortisol and ACTH (p's < 0.05) and attenuated stress cue-induced rises in cortisol (p < 0.05) versus placebo. Finally, in those without lifetime anxiety disorder, the placebo group showed stress- and alcohol cue-induced increases in cortisol (p's < 0.05), while the prazosin group did not. CONCLUSIONS:Prazosin may attenuate stress cue-induced alcohol craving and anxiety during early abstinence while improving adrenergic and stress system function, effects which are independent of a history of lifetime anxiety disorders.
Authors: George A Kenna; Carolina L Haass-Koffler; William H Zywiak; Steven M Edwards; Michael B Brickley; Robert M Swift; Lorenzo Leggio Journal: Addict Biol Date: 2015-06-02 Impact factor: 4.280
Authors: Tracy L Simpson; Carol A Malte; Bergetta Dietel; Dana Tell; Ian Pocock; Robert Lyons; Dana Varon; Murray Raskind; Andrew J Saxon Journal: Alcohol Clin Exp Res Date: 2015-04-01 Impact factor: 3.455
Authors: Tracy L Simpson; Andrew J Saxon; Cynthia Stappenbeck; Carol A Malte; Robert Lyons; Dana Tell; Steven P Millard; Murray Raskind Journal: Am J Psychiatry Date: 2018-08-29 Impact factor: 18.112
Authors: A D Lê; Douglas Funk; Walter Juzytsch; Kathleen Coen; Brittany M Navarre; Carlo Cifani; Yavin Shaham Journal: Psychopharmacology (Berl) Date: 2011-02-12 Impact factor: 4.530
Authors: Rajita Sinha; Helen C Fox; Kwangik A Hong; Keri Bergquist; Zubin Bhagwagar; Kristen M Siedlarz Journal: Neuropsychopharmacology Date: 2008-06-18 Impact factor: 7.853
Authors: Jordan A Brown; Nicholas Petersen; Samuel W Centanni; Allie Y Jin; Hye Jean Yoon; Stephanie A Cajigas; Michelle N Bedenbaugh; Joseph R Luchsinger; Sachin Patel; Erin S Calipari; Richard B Simerly; Danny G Winder Journal: Neuropsychopharmacology Date: 2022-09-09 Impact factor: 8.294
Authors: Rajita Sinha; Stephanie Wemm; Nia Fogelman; Verica Milivojevic; Peter M Morgan; Gustavo A Angarita; Gretchen Hermes; Helen C Fox Journal: Am J Psychiatry Date: 2020-11-19 Impact factor: 18.112